<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686842</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-059</org_study_id>
    <secondary_id>U01CA121947</secondary_id>
    <secondary_id>CDR0000596565</secondary_id>
    <secondary_id>PTC299-ONC-005-KS</secondary_id>
    <nct_id>NCT00686842</nct_id>
  </id_info>
  <brief_title>PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma</brief_title>
  <official_title>A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to
      see how well it works in treating patients with HIV-related Kaposi sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To define the safety and toxicity of anti-VEGF small molecule PTC299 in patients with
           HIV-related Kaposi sarcoma.

        -  To establish the maximum tolerated dose of this drug in these patients.

        -  To estimate the response rate in patients treated with this drug.

      Secondary

        -  To describe the pharmacokinetics of this drug in these patients.

        -  To describe the effects of this drug on serum and plasma VEGF, VEGFR, and cytokine
           profiles in these patients.

        -  To describe the effects of this drug on HIV and KSHV viral loads in these patients.

        -  To describe the effects of this drug on T-lymphocyte subsets (i.e., CD4 and CD8) in
           these patients.

        -  To describe the effects of this drug on VEGF, VEGFR-2 and -3, phospho-Akt, p53, and
           HIF-1α expression and tumor cell proliferation, as measured by Ki-67 staining, in tumor
           biopsy samples obtained from these patients.

        -  To describe the effects of this drug on viral gene expression and cellular gene
           transcription, as measured by real-time quantitative PCR-based profiling, in tumor
           biopsy samples obtained from these patients.

      OUTLINE: This is a multicenter, phase I dose-escalation study of anti-VEGF small molecule
      PTC299 followed by a phase II study.

      Patients receive oral anti-VEGF small molecule PTC299 twice daily on days 1-28. Treatment
      repeats every 28 days for up to 12 courses in the absence of disease progression or
      unacceptable toxicity. Patients who do not demonstrate an objective response of their Kaposi
      sarcoma (KS) lesions after 6 courses of treatment are removed from the study.

      Patients undergo blood sample collection and punch biopsies periodically during study for
      correlative laboratory studies. Biopsy samples are assessed for VEGF, VEGFR-2, VEGFR-3,
      phospho-Akt, KSHV LANA, orf59, p53, and HIF-1α expression by IHC; tumor cell proliferation by
      Ki-67 staining; and viral gene expression at the messenger RNA level and KSHV transcription
      by real-time quantitative PCR-based profiling. Blood samples are assessed for
      pharmacokinetics and levels of secreted cytokines or other potential serum markers
      characteristic for KS.

      After completion of study treatment, patients are followed at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug supply unavailable.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Toxicity of Anti-VEGF Small Molecule PTC299</measure>
    <time_frame>All study visits</time_frame>
    <description>Patients who experienced an adverse event of grade 3 or greater</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>After each group of 3 subjects completes cycle 1 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to Treatment</measure>
    <time_frame>After each 28-day cycle of treatment and at discontinuation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Days 1, 15, 28, 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Study Drug on Serum and Plasma VEGF, VEGFR, and Cytokine Profiles</measure>
    <time_frame>On the first day of every 28-day cycle of treatment, Day 15, and treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Study Drug on HIV and KSHV Viral Loads</measure>
    <time_frame>Screening, end of cycle 1, end of every third cycle thereafter, and treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Study Drug on T-lymphocyte Subsets (i.e., CD4 and CD8)</measure>
    <time_frame>Screening, day 29, every 3 cycles thereafter, and at treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Study Drug on VEGF, VEGFR-2 and -3, Phospho-Akt, p53, and HIF-1α Expression and Tumor Cell Proliferation, as Measured by Ki-67 Staining, in Tumor Biopsy Samples</measure>
    <time_frame>Screening and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Study Drug on Viral Gene Expression and Cellular Gene Transcription, as Measured by Real-time Quantitative PCR-based Profiling, in Tumor Biopsy Samples</measure>
    <time_frame>Screening and day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Kaposi's Sarcoma</condition>
  <arm_group>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study - all subjects received PTC299</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGF inhibitor PTC299</intervention_name>
    <description>20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.</description>
    <arm_group_label>VEGF Inhibitor PTC299</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Biopsy-proven Kaposi sarcoma (KS) involving the skin (with or without lymph node),
             oral cavity, gastrointestinal (GI) tract, and/or lung

               -  Patients with GI and/or pulmonary involvement must be asymptomatic or minimally
                  symptomatic and not require systemic cytotoxic chemotherapy

          -  Has at least five bidimensionally measurable cutaneous lesions that have not been
             previously irradiated AND can be used as indicator lesions

               -  Must have a sufficient number of non-indicator cutaneous lesions measuring ≥ 4 x
                  4 mm available to obtain a total of four 3-mm punch biopsies (two at baseline and
                  two during the course of study treatment)

          -  Serologic documentation of HIV infection, as evidenced by positive ELISA, western
             blot, or other federally approved licensed HIV test OR a detectable blood level of HIV
             RNA

          -  Patients receiving antiretroviral therapy for HIV infection are eligible provided they
             have been on a stable regimen for ≥ 12 weeks prior to study entry AND there is no
             evidence of improvement in KS during those 12 weeks or there is evidence of
             progression of KS within the immediate 4 weeks prior to study entry

          -  No symptomatic visceral KS requiring cytotoxic therapy

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Life expectancy ≥ 3 months

          -  Absolute neutrophil count ≥ 1,000/mm³

          -  Platelet count ≥ 75,000/mm³

          -  Hemoglobin ≥ 8 g/dL

          -  Creatinine ≤ 2.0 mg/dL

          -  Total bilirubin normal (grade 0)

               -  No specific limit of total serum bilirubin for patient receiveing indinavir or
                  atazanavir therapy AND direct serum bilirubin ≤ 30% of total bilirubin

          -  AST and ALT ≤ 2.5 times upper limit of normal (grade 1)

          -  INR and aPTT normal

          -  Proteinuria &lt; 2+

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for up to 3
             months after completion of study treatment

          -  Capable of complying with the study, in the opinion of the investigator

          -  No acute, active opportunistic infection (other than oral thrush or genital herpes)
             within the past 14 days

          -  No other concurrent neoplasia requiring cytotoxic therapy

          -  No history of any of the following:

               -  Myocardial infarction

               -  Severe/unstable angina

               -  Coronary/peripheral artery bypass graft

               -  Symptomatic congestive heart failure

               -  Cerebrovascular accident

               -  Transient ischemic attack

               -  Pulmonary embolism

               -  Deep vein thrombosis

               -  Other significant thromboembolic event

          -  No known coagulopathy or bleeding diathesis

          -  No history of CNS, pulmonary, GI, or urinary bleeding

          -  No known history of drug-induced liver injury

          -  Resting systolic blood pressure ≤ 160 mm Hg or diastolic blood pressure ≤ 100 mm Hg

          -  No history of or ongoing clinically significant illness, medical condition, surgical
             history, physical finding, ECG finding, or laboratory abnormality that, in the opinion
             of the investigator, could affect the safety of the patient, alter the absorption of
             the study drug, or impair the assessment of study results

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior and no other concurrent anti-neoplastic therapy for KS,
             including chemotherapy, radiotherapy, local therapy, or biological therapy

          -  More than 60 days since prior local therapy for any KS-indicator lesion unless the
             lesion has clearly progressed since treatment

               -  Any prior local therapy for indicator lesions (regardless of the elapsed time)
                  should not be allowed unless there is evidence of clear-cut progression of that
                  lesion

          -  More than 28 days since prior and no other concurrent investigational drugs or therapy
             (other than antiretroviral therapy or agents available on a treatment IND)

          -  More than 30 days since prior major surgery and recovered

          -  More than 14 days since prior treatment for an acute infection (other than oral thrush
             or genital herpes) or other serious medical illness

          -  No concurrent surgical procedures

          -  No concurrent systemic corticosteroid therapy, other than replacement doses

          -  No concurrent anticoagulant therapy, including warfarin, heparin (including low
             molecular weight heparin), or antiplatelet drugs (e.g., clopidogrel bisulfate)

               -  Concurrent aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) allowed
                  provided the dose does not exceed the maximum recommended dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan E. Krown, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical AIDS Research and Education (CARE) Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE; AIDS Malignancy Consortium (AMC)-059 Study Team. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 1;72(1):52-7. doi: 10.1097/QAI.0000000000000918.</citation>
    <PMID>26689971</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>January 30, 2012</results_first_submitted>
  <results_first_submitted_qc>January 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2012</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VEGF Inhibitor PTC299</title>
          <description>Single arm study - all subjects received PTC299</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VEGF Inhibitor PTC299</title>
          <description>Single arm study - all subjects received PTC299</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Toxicity of Anti-VEGF Small Molecule PTC299</title>
        <description>Patients who experienced an adverse event of grade 3 or greater</description>
        <time_frame>All study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VEGF Inhibitor PTC299</title>
            <description>Single arm study - all subjects received PTC299</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity of Anti-VEGF Small Molecule PTC299</title>
          <description>Patients who experienced an adverse event of grade 3 or greater</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <time_frame>After each group of 3 subjects completes cycle 1 of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response to Treatment</title>
        <time_frame>After each 28-day cycle of treatment and at discontinuation of therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <time_frame>Days 1, 15, 28, 57</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Study Drug on Serum and Plasma VEGF, VEGFR, and Cytokine Profiles</title>
        <time_frame>On the first day of every 28-day cycle of treatment, Day 15, and treatment discontinuation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Study Drug on HIV and KSHV Viral Loads</title>
        <time_frame>Screening, end of cycle 1, end of every third cycle thereafter, and treatment discontinuation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Study Drug on T-lymphocyte Subsets (i.e., CD4 and CD8)</title>
        <time_frame>Screening, day 29, every 3 cycles thereafter, and at treatment discontinuation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Study Drug on VEGF, VEGFR-2 and -3, Phospho-Akt, p53, and HIF-1α Expression and Tumor Cell Proliferation, as Measured by Ki-67 Staining, in Tumor Biopsy Samples</title>
        <time_frame>Screening and day 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Study Drug on Viral Gene Expression and Cellular Gene Transcription, as Measured by Real-time Quantitative PCR-based Profiling, in Tumor Biopsy Samples</title>
        <time_frame>Screening and day 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VEGF Inhibitor PTC299</title>
          <description>Single arm study - all subjects received PTC299</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreases</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increases</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Krown, MD, Protocol Chair</name_or_title>
      <organization>AMC</organization>
      <phone>301-251-1161</phone>
      <email>amcpm@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

